Moberg Pharma Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 5

Employees

  • Stock Symbol
  • MOB

Stock Symbol

  • Investments
  • 10

  • Share Price
  • $1.06
  • (As of Friday Closing)

Moberg Pharma General Information

Description

Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Contact Information

Formerly Known As
Moberg Derma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Gustavslundsvägen 50, 5th floor
  • 167 51 Bromma
  • Sweden
+46
Primary Industry
Pharmaceuticals
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Gustavslundsvägen 50, 5th floor
  • 167 51 Bromma
  • Sweden
+46

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Moberg Pharma Stock Performance

As of 13-Nov-2026, Moberg Pharma’s stock price is $1.06. Its current market cap is $50.2M with 47.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.06 $1.04 $0.85 - $1.52 $50.2M 47.2M 65.6K -$0.04

Moberg Pharma Financials Summary

As of 30-Sep-2026, Moberg Pharma has a trailing 12-month revenue of $1.97M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 32,256 27,156 15,407 32,751
Revenue 1,972 1,378 928 0
EBITDA (1,660) (2,617) (2,223) (2,386)
Net Income (2,026) (2,772) (24,122) (1,984)
Total Assets 67,851 74,144 63,995 63,512
Total Debt 130 277 375 474
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Moberg Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Moberg Pharma‘s full profile, request access.

Request a free trial

Moberg Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based
Pharmaceuticals
Bromma, Sweden
5 As of 2026

Uppsala, Sweden
 

Friedrichsdorf, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Moberg Pharma Competitors (18)

One of Moberg Pharma’s 18 competitors is Orexo, a Formerly VC-backed company based in Uppsala, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orexo Formerly VC-backed Uppsala, Sweden
axicorp Corporate Backed or Acquired Friedrichsdorf, Germany
Novartis Corporation Basel, Switzerland
Pfizer (Vienna) Corporation Vienna, Austria
Indivior Corporate Backed or Acquired North Chesterfield, VA
You’re viewing 5 of 18 competitors. Get the full list »

Moberg Pharma Patents

Moberg Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260102363-A1 Treatment method and antifungal composition Active 08-Dec-2020
AU-2021396584-A1 Treatment regimen for onchyomycosis using allylamine antifungal compositions Inactive 08-Dec-2020
AU-2021396584-A9 Treatment regimen for onchyomycosis using allylamine antifungal compositions Inactive 08-Dec-2020
CA-3201760-A1 Treatment regimen for onchyomycosis using allylamine antifungal compositions Pending 08-Dec-2020
EP-4259116-A1 Treatment regimen for onchyomycosis using allylamine antifungal compositions Pending 08-Dec-2020 A61K47/12
To view Moberg Pharma’s complete patent history, request access »

Moberg Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Moberg Pharma Investments & Acquisitions (10)

Moberg Pharma’s most recent deal was a Corporate with Allderma. The deal was made on 08-Nov-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Allderma 08-Nov-2023 Corporate Pharmaceuticals
Prestige Consumer Healthcare (Dermoplast Pain Relieving Spray) 31-Dec-2016 Corporate Asset Purchase Buildings and Property
New Skin 08-Jul-2016 Merger/Acquisition Buildings and Property
Prestige Brands (New Skin, Fiber Choice, PediaCare) 08-Jul-2016 Corporate Asset Purchase Buildings and Property
Fiber Choice 30-Jun-2016 Merger/Acquisition Food Products
You’re viewing 5 of 10 investments and acquisitions. Get the full list »

Moberg Pharma ESG

Risk Overview

Risk Rating

Updated July, 31, 2023

33.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Moberg Pharma’s complete esg history, request access »

Moberg Pharma Exits (3)

Moberg Pharma’s most recent exit was on 08-Nov-2023 from Allderma. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Allderma 08-Nov-2023 Completed
Fiber Choice 30-Jun-2016 Completed
Moberg Pharma (Balmex) 24-Apr-2015 Corporate Asset Purchase Completed
To view Moberg Pharma’s complete exits history, request access »

Moberg Pharma FAQs

  • When was Moberg Pharma founded?

    Moberg Pharma was founded in 2006.

  • Where is Moberg Pharma headquartered?

    Moberg Pharma is headquartered in Bromma, Sweden.

  • What is the size of Moberg Pharma?

    Moberg Pharma has 5 total employees.

  • What industry is Moberg Pharma in?

    Moberg Pharma’s primary industry is Pharmaceuticals.

  • Is Moberg Pharma a private or public company?

    Moberg Pharma is a Public company.

  • What is Moberg Pharma’s stock symbol?

    The ticker symbol for Moberg Pharma is MOB.

  • What is the current stock price of Moberg Pharma?

    As of 13-Nov-2026 the stock price of Moberg Pharma is $1.06.

  • What is the current market cap of Moberg Pharma?

    The current market capitalization of Moberg Pharma is $50.2M.

  • What is Moberg Pharma’s current revenue?

    The trailing twelve month revenue for Moberg Pharma is $1.97M.

  • Who are Moberg Pharma’s competitors?

    Orexo, axicorp, Novartis, Pfizer (Vienna), and Indivior are some of the 18 competitors of Moberg Pharma.

  • What is Moberg Pharma’s annual earnings per share (EPS)?

    Moberg Pharma’s EPS for 12 months was -$0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process